Literature DB >> 2120729

Sentinel surveillance of HIV infection among new inmates and implications for policies of corrections facilities.

K K Patel1, C Hutchinson, D G Sienko.   

Abstract

Seroprevalence surveys of incoming inmates provide useful sentinel information on human immunodeficiency virus (HIV) infection rates among groups that practice HIV-associated high-risk behaviors. In addition, such data are beneficial to corrections officials in the formulation of institutional policies to prevent HIV infection. Inmates entering the Michigan corrections system from December 1987 to March 1988 participated in blind, anonymous serosurveys for HIV infection. Eight of 802 entering inmates (1.0 percent) were seropositive; most seropositive persons reported intravenous drug use. The most common risk behaviors reported by study participants were intravenous drug use (20.0 percent), multiple sexual partners (37.1 percent), and infrequent (that is, never or seldom) use of condoms (82.6 percent). Women reported the highest rates of intravenous drug use (35.1 percent) and needle-sharing (19.4 percent). Results from this study indicate that in spite of wide-spread HIV-associated risk behaviors, the extent of HIV-seropositivity among incoming inmates in Michigan is relatively low. Such data suggest that there is still time to impact the course of the AIDS epidemic among high-risk groups in States where the prevalence of HIV infection is relatively low. The data also indicate that the potential for HIV spread in correctional facilities is noteworthy and that HIV prevention education and substance abuse treatment services are needed in corrections facilities.

Entities:  

Mesh:

Year:  1990        PMID: 2120729      PMCID: PMC1580106     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  9 in total

Review 1.  Aerosol pentamidine.

Authors:  D Armstrong; E Bernard
Journal:  Ann Intern Med       Date:  1988-12-01       Impact factor: 25.391

Review 2.  AIDS and behavioral change to reduce risk: a review.

Authors:  M H Becker; J G Joseph
Journal:  Am J Public Health       Date:  1988-04       Impact factor: 9.308

Review 3.  AIDS commentary. Azidothymidine.

Authors:  M S Hirsch
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

4.  Prevalence and incidence of HTLV-III infection in a prison.

Authors:  P W Kelley; R R Redfield; D L Ward; D S Burke; R N Miller
Journal:  JAMA       Date:  1986 Oct 24-31       Impact factor: 56.272

5.  Seroepidemiology of hepatitis B in Tennessee prisoners.

Authors:  M D Decker; W K Vaughn; J S Brodie; R H Hutcheson; W Schaffner
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

6.  Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco.

Authors:  R E Chaisson; A R Moss; R Onishi; D Osmond; J R Carlson
Journal:  Am J Public Health       Date:  1987-02       Impact factor: 9.308

7.  Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS.

Authors:  M A Fischl; G M Dickinson; L La Voie
Journal:  JAMA       Date:  1988-02-26       Impact factor: 56.272

8.  Seroprevalence of HIV antibody among individuals entering the Iowa Prison System.

Authors:  G E Glass; W J Hausler; P L Loeffelholz; C E Yesalis
Journal:  Am J Public Health       Date:  1988-04       Impact factor: 9.308

9.  Hepatitis B in Wisconsin male prisoners: considerations for serologic screening and vaccination.

Authors:  R F Anda; S B Perlman; D J D'Alessio; J P Davis; V N Dodson
Journal:  Am J Public Health       Date:  1985-10       Impact factor: 9.308

  9 in total
  2 in total

1.  Effects of incarceration on HIV-infected individuals.

Authors:  M M Griffin; J G Ryan; V S Briscoe; K M Shadle
Journal:  J Natl Med Assoc       Date:  1996-10       Impact factor: 1.798

2.  HIV infection among women in prison: an assessment of risk factors using a nonnominal methodology.

Authors:  C A Hankins; S Gendron; M A Handley; C Richard; M T Tung; M O'Shaughnessy
Journal:  Am J Public Health       Date:  1994-10       Impact factor: 9.308

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.